Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study ofTP53Gene Therapy
| Autor: | Xiuqin Li, Yu Xia, Zhenhua Du, Xinyan Wang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
0301 basic medicine medicine.medical_specialty Genetic enhancement medicine.medical_treatment Gendicine Bleomycin Gastroenterology Adenoviridae 03 medical and health sciences chemistry.chemical_compound Stable Disease Internal medicine Genetics medicine Humans Molecular Biology Epirubicin Cisplatin Chemotherapy Uterine sarcoma business.industry Liver Neoplasms Sarcoma Genetic Therapy Middle Aged medicine.disease Combined Modality Therapy Progression-Free Survival Recombinant Proteins 030104 developmental biology chemistry Uterine Neoplasms Molecular Medicine Female Tumor Suppressor Protein p53 business medicine.drug |
| Zdroj: | Human Gene Therapy. 29:242-250 |
| ISSN: | 1557-7422 1043-0342 |
| DOI: | 10.1089/hum.2017.206 |
| Popis: | This study evaluated the efficacy of rAd-p53 (Gendicine®) followed by chemotherapy for the treatment of uterine sarcoma. Twelve cases of uterine sarcoma treated at Shengjing Hospital were retrospectively analyzed. Among the 12 patients, one had primary cancer, and 11 had recurrent cancer. For the recurrent cases, the interval between the first operation and diagnosis of recurrence, or progression-free survival time 1 (PFS1), was 1–18 months (median 3 months). All patients were treated with local application of rAd-p53 followed by chemotherapy (local injection of bleomycin and i.v. infusion of cisplatin, epirubicin, and isocyclophosphamide). Efficacy was evaluated, and the rates of complete remission (CR) and partial remission (PR) were calculated. During follow-up, PFS time 2 (PFS2) after the baseline period and overall survival (OS) time after the baseline period of rAd-p53 treatment data were obtained. The treatment resulted in one CR, seven PR, three with stable disease (SD), and one with progressive d... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|